Journal of Medicinal Chemistry · 2008 · 100 citations · 38 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryStructural BiologyStructure-activity RelationshipsEnzyme InhibitionFragment-based Drug DesignLigand BindingLigand-based DesignMolecular DockingPotency OptimizationAntiproliferative AgentsAntiproliferative Drug ActionKinase Inhibitor Library DesignMolecular CrystallographyProtein Kinase InhibitorsPyrimidine AnalogsPyrimidine AnaloguesPyrimidine Chemistry
Fragment-based screening identified 7-azaindole as a protein kinase B inhibitor scaffold. Fragment elaboration using iterative crystallography of inhibitor-PKA-PKB chimera complexes efficiently guided improvements in the potency and selectivity of the compounds, resulting in the identification of nanomolar 6-(piperidin-1-yl)purine, 4-(piperidin-1-yl)-7-azaindole, and 4-(piperidin-1-yl)pyrrolo[2,3- d]pyrimidine inhibitors of PKBbeta with antiproliferative activity and showing pathway inhibition in cells. A divergence in the binding mode was seen between 4-aminomethylpiperidine and 4-aminopiperidine containing molecules. Selectivity for PKB vs PKA was observed with 4-aminopiperidine derivatives, and the most PKB-selective inhibitor (30-fold) showed significantly different bound conformations between PKA and PKA-PKB chimera.
38
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Philip Skehan, Ritsa Storeng, Dominic A. Scudiero et al. · JNCI Journal of the National Cancer Institute · 1990 · 9.8K citations
Medicine, Oncology, Pharmacology +10
Arup K. Ghose, Gordon M. Crippen · Journal of Chemical Information and Computer Sciences · 1987 · 808 citations
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Qi-Wen Fan, Zachary A. Knight, David Goldenberg et al. · Cancer Cell · 2006 · 584 citations · Full text
Medicine, Neuroscience, Oncology +10